{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 14,
  "pageCount": 24,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The schematic illustrates a dose escalation study with three cohorts of 10 patients each, separated by safety review committee (SRC) checkpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/14",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.48,
        "x": 0.48,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Study Schematic showing screening, three treatment arms (200mg, 300mg, 400mg BID), SRC checkpoints, and follow-up periods.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0e15cd9-bd85-416c-93ec-1d2b8c25f7d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "Design: Open label, dose escalation design; 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks on treatment; Generally healthy male and female patients aged 18-75 with Dx'd Cold Induced Urticaria",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5642a9e5-4744-4493-90df-5f7a49cec663",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.03,
        "y": 0.55
      },
      "kind": "list",
      "text": "Objectives: Safety and Tolerability; Mean reduction in critical temperature threshold (CTT) using the TempTest system; PK, serum tryptase; Clinical outcome measures (e.g., ColdUAS, ColdU-QoL)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79d1a641-3f80-4584-8aa5-2af0ac110ccb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.48,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "SRC=safety review committee",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8653d9e-c3a9-4e26-9669-6f246c211ad1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1b Chronic Inducible Urticaria (CIndU) Study Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7723ad48-e8c9-4d50-a432-c26c3e854037",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "18db4989-fb48-4b98-b91e-3d26fb65b58b",
      "evidence": "Schematic representation of patient cohorts, dosing, and follow-up",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1637e937-fd9b-4682-939c-d684884ac925",
      "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.",
      "position": 0,
      "objective": "What is the cost of not treating mast cell-mediated diseases effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}